- $485.88m
- $260.49m
Neurogene Inc expected to post a loss of $1.17 a share - Earnings Preview
Brief: Neurogene Announces Expansion, Plans For More Rapid Patient Enrollment Of Rett Syndrome Gene Therapy Clinical Trial
Brief: Ecor1 Capital Reports 9.99% Passive Stake In Neurogene As Of December 18, 2023 - SEC Filing
Brief: Neurogene Inc - Ended 2023 In A Strong Financial Position With Approximately $200 Million In Cash And Runway Into 2H26
Brief: Neoleukin Therapeutics Announces 1-For-4 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Ford, Energy firms, Natgas firms
U.S. STOCKS ON THE MOVE-China ADRs, Wayfair, Seagen
Neoleukin Therapeutics down after announcing reverse stock split
Brief: Neoleukin Therapeutics Announces 1-For-5 Reverse Stock Split
Neoleukin Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Pieris Pharma, Microsoft, Energy sector
U.S. STOCKS ON THE MOVE-Medtronic, Morgan Stanley, Bank of America
Neoleukin falls after deal to merge with genetic medicine developer
Neoleukin falls after deal to merge with genetic medicine developer
Brief: Neurogene And Neoleukin Announce Definitive Merger Agreement
Neoleukin Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Neoleukin Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Neoleukin Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Neoleukin Therapeutics Inc reports results for the quarter ended in December - Earnings Summary